TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1818424
Drug: IFN maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN maintenance therapy (3 x 10(6) I.U. INTRON‐A by subcutaneous injection three times a week for 4 months)
Study: 7193447
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of methotrexate (50 mg/sq m orally) and cisplatin (intravenously 24 hours later), repeated four times at weekly intervals.
Study: 7193447
Drug: Therapeutic postoperative
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic postoperative radiation therapy (for 43 patients operated on).
Study: 26539650
Drug: simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20 mg
Study: 26539650
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg
Study: 9777110
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg/day
Study: 14998843
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy
Study: 25089351
Drug: Anti-VEGF treatment-naïve
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment-naïve
Study: 22348256
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate after 7 days washout (treatment C)
Study: 22935621
Drug: 400-μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-μg sublingual misoprostol
Study: 16215602
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acids supplement for 8 weeks
Study: 29460813
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement for 8 weeks
Study: 12164090
Drug: Amlodipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2 months treatment)
Study: 12164090
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (intra-arterial infusion)
Study: 12164090
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of L-NMMA (inhibitor of nitric oxide synthase)
Study: 9931520
Drug: Morphine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (140 microg/kg over a 1-hour period followed by 20 microg/kg/hr)
Study: 1968694
Drug: Alcuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium (0.03 mg/kg)
Study: 619946
Drug: Tubocurarine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine (0.05 mg/kg)
Study: 1968694
Drug: Vecuronium (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.01 mg/kg)
Study: 27445072
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (group A)
Study: 27445072
Drug: Brinzolamide/brimonidine fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide/brimonidine fixed combination (group B)
Study: 26522035
Drug: Mini-implant anchored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implant anchored Forsus Fatigue Resistant Device (FMI)
Study: 23377333
Drug: Scar product
Normalized name: Mederma Advanced Scar Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scar product (twice-daily application)
Study: 17694726
Drug: Indiplon 10
Normalized name: Indiplon
DrugBank: Indiplon (DB12590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indiplon 10 mg
Study: 17694726
Drug: Indiplon 20
Normalized name: Indiplon
DrugBank: Indiplon (DB12590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indiplon 20 mg
Study: 1618258
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg
Study: 30278560
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg/kg over 10 min) followed by maintenance (0.5 μg/kg/h)
Study: 30278560
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg) followed by dexmedetomidine maintenance (0.5 μg/kg/h)
Study: 28393775
Drug: Sufentanil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.1 mcg/kg bolus followed by 0.1 mcg/h infusion)
Study: 21613795
Drug: HD200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD200 (200 mg/dl)
Study: 21613795
Drug: HD100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD100 (100 mg/dl)
Study: 18362317
Drug: Removal in
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal in combination with a 'biological detoxification' therapy with high doses of vitamins and trace elements
Study: 15000440
Drug: BCAA (14.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (14.4 g/day)
Study: 11061609
Drug: I-CHOPE regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-CHOPE regimen (doxorubicin 10 mg/m2/day, vincristine 0.28 mg/m2/day, etoposide 48 mg/m2/day, cyclophosphamide 750 mg/m2 on day 6, prednisone 100 mg/day on days 1-5)
Study: 31838498
Drug: TTV loads
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTV loads ≥4log copies/ml in males
Study: 25491929
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg nicotine patch
Study: 17370487
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection at cervical Jiaji points and routine acupuncture
Study: 12740311
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) diet (meals providing carbohydrate (CHO) of 1.75 g/kg)
Study: 8648356
Drug: Uft group
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uft group (1-year oral administration of UFT 400 mg/kg)
Study: 22943608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgical treatment only)
Study: 6135989
Drug: Aspirin (324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (324 mg in buffered solution daily for 12 weeks)
Study: 3000793
Drug: Propranolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 240 mg
Study: 27555178
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 μg/kg
Study: 24875890
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg
Study: 24121920
Drug: Intra-oral electrostimulator
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral electrostimulator (GenNarino)
Study: 14705720
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneously once daily for 10 days)
Study: 8976353
Drug: Vein Patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein Patch Closure (SVP and JVP)
Study: 8976353
Drug: Polytetrafluoroethylene Patch
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene Patch Closure (PTFE‐PC)
Study: 8976353
Drug: Vein Patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein Patch Closure (JVP)
Study: 1468239
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg etodolac SR once daily for 4 weeks
Study: 1468239
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac SR
Study: 6478435
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (2 courses of chemotherapy: cisplatin 2 mg/kg; methotrexate 280‐560 mg/m2 with leucovorin rescue; bleomycin 30 mu X 3) followed by radiation therapy and surgery
Study: 9071898
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy
Study: 6478435
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (preoperative radiation therapy followed by surgery)
Study: 16019363
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined CEE/MPA 0.625 mg/day and 5 mg/day
Study: 10485779
Drug: Ritonavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (200 mg three times on the first day and 300 mg three times on the second day)
Study: 8765815
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (220 micrograms or 440 micrograms)
Study: 31201146
Drug: Dimethicone (500
Normalized name: PEG-10 DIMETHICONE (500 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethicone (500 mg, three times a day for 2 weeks)
Study: 31201146
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg, three times a day for 2 weeks)
Study: 25197015
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant placement
Study: 19898698
Drug: Standard-dose simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose simvastatin (20 mg/day to 40 mg/day)
Study: 17123915
Drug: Fluoride-containing materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-containing materials (e.g., Fuji IX - FIX)
Study: 12212341
Drug: Generic tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic tablets (Group B)
Study: 9258217
Drug: Mitomycin, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin, 0.2 mg/mL, applied for 2 minutes
Study: 9258217
Drug: Mitomycin, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin, 0.4 mg/mL, applied for 4 minutes
Study: 9258217
Drug: Mitomycin, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin, 0.4 mg/mL, applied for 2 minutes
Study: 8438713
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser coronary angioplasty (ELCA) followed by adjunctive PTCA
Study: 27009938
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by Interval Debulking Surgery (NACT-IDS)
Study: 25760680
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (insulin 0.1 IU kg(‐1) h(‐1) and an infusion of 30% dextrose and 80 mmol l(‐1) potassium at 0.5 ml kg(‐1) h(‐1))
Study: 11696690
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution
Study: 19196892
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy
Study: 7838644
Drug: LAT gel
Normalized name: Pleo lat whole
DrugBank: Bacillus cereus (DB19245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT gel (4% lidocaine, 1:2000 adrenaline, 0.5% tetracaine)
Study: 7838644
Drug: TAC gel
Normalized name: Zantac GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC gel (0.5% tetracaine, 1:2000 adrenaline, 11.8% cocaine)
Study: 7838644
Drug: LAT gel
Normalized name: Pleo lat whole
DrugBank: Bacillus cereus (DB19245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT gel
Study: 7838644
Drug: TAC gel
Normalized name: Zantac GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC gel
Study: 7838644
Drug: LAT gel
Normalized name: Pleo lat whole
DrugBank: Bacillus cereus (DB19245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT gel and TAC gel
Study: 699788
Drug: Propranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3 x 40 mg/d or 3 x 80 mg/d)
Study: 7261940
Drug: Propranolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol treatment
Study: 23168366
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (2.5 mg/kg per week equivalent, either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, intravenously)
Study: 14673218
Drug: Trazodone CR
Normalized name: trazodone Extended Release Oral Tablet [Molipaxin CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone CR (150 mg)
Study: 10807482
Drug: Right Unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right Unilateral ECT (RUL ECT) at high dosage (150% or 500% above seizure threshold)
Study: 10807482
Drug: Bilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ECT (BL ECT) at high dosage (150% above seizure threshold)
Study: 10807482
Drug: Low-dosage Unilateral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage Unilateral ECT
Study: 10807482
Drug: Moderate-dosage Unilateral
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dosage Unilateral ECT
Study: 7695258
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg genaconazole intravenous infusion
Study: 3234625
Drug: Synthetic salmon
Normalized name: Synthetic salmon calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic salmon calcitonin (415 pmol bolus injection followed by infusion to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Study: 29290000
Drug: Fosfomycin tromethamine
Normalized name: FOSFOMYCIN TROMETHAMINE
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin tromethamine (3 g, two oral doses)
Study: 29290000
Drug: Standard-of-care antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care antibiotic therapy (control group)
Study: 14685040
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy with Cry j 1 at doses of 0.01 microg/ml, 0.1 microg/ml, 1 microg/ml, and 10 microg/ml.
Study: 14685040
Drug: Hyposensitization therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy.
Study: 7942121
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro data at glucose concentrations > or = 13.8 mmol/L
Study: 3496186
Drug: Enteric-coated fenoprofen
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated fenoprofen calcium (600 mg q.i.d.)
Study: 10811675
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m²
Study: 8772621
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in overweight subgroup)
Study: 30153782
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid group (≥ 3250 mL of fluid administered)
Study: 9459253
Drug: Lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 3 mL (2%)
Study: 318908
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg
Study: 7707111
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg orally, twice daily for 3 months
Study: 2496357
Drug: Aspirin-dipyridamole (990
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-dipyridamole (990 mg/225 mg daily)
Study: 580589
Drug: meproscillarin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: meproscillarin (4 X 0.25 mg/d for 7 days)
Study: 31253207
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion at 1.5 times C0
Study: 31253207
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion at 2 times C0
Study: 31253207
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion at 2.5 times C0
Study: 21515482
Drug: Fluorouracil (PF)
Normalized name: FLUOROURACIL (PF) 50MG/ML INJ
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (PF) regimen with concurrent radiotherapy
Study: 8317719
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine infusion (0.5 mL saline bolus followed by 200 micrograms morphine infusion in 24 h)
Study: 8317719
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine bolus (200 micrograms morphine as a single bolus followed by 3 mL saline infusion in 24 h)
Study: 31570566
Drug: Telapristone acetate
Normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telapristone acetate (TPA) 12 mg daily for 2 to 10 weeks
Study: 25456710
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (exercise training + ventilation)
Study: 21890575
Drug: STN‐DBS implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: STN‐DBS implants
Study: 20167117
Drug: Allopurinol 500
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 500 mg IV
Study: 18056144
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release methylphenidate (Ritalin), administered three times a day
Study: 335225
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (control)
Study: 15728647
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment
Study: 11206101
Drug: Trimetazidine IV
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine IV infusion started before PTCA and continued for 48 hours
Study: 31631029
Drug: Cardiovascular medication
Normalized name: CARDIOVASCULAR MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular medication use
Study: 26833462
Drug: NNC0114‐0005 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0114‐0005 (25 mg/kg)
Study: 20975266
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous CD34+ stem cells
Study: 20975266
Drug: Intracoronary saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary saline injections (placebo control)
Study: 6778345
Drug: PCP-8 (octavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCP-8 (octavalent vaccine) administered at 25 micrograms of each serotype at 3-6 months and again at 18-24 months.
Study: 6778345
Drug: PCP-7 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCP-7 or PCP-8 administered to 44 infants followed for two years.
Study: 28348190
Drug: Swallowing Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Swallowing Intervention Package (SIP) delivered pre-treatment
Study: 19806814
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of aprotinin (500,000 KIU, 50 mL)
Study: 30110007
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (50 mL)
Study: 17052775
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.5 mg/day (group A)
Study: 17052775
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.5 mg/day (group A) in patients with MTHFR 677TT mutation
Study: 11601949
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of medications and health conditions, details not available
Study: 30096354
Drug: Intravitreous ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous ranibizumab (0.5 mg)
Study: 19435154
Drug: Motor coordination
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor coordination training for 20 minutes daily over 3 weeks
Study: 360495
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of 10% glycerol in 0.9% NaCl‐‐5% glucose solutions administered twice daily for 6 days to 26 patients
Study: 30916203
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypertension
Study: 25413168
Drug: Cognitive‐behavioural training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural training programme for pain management (6 weekly group sessions supervised by a psychologist and a physiotherapist)
Study: 23331443
Drug: ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 2.5 mg daily
Study: 19671411
Drug: Oxymatrine Capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine Capsule, 0.4 g once a day for 3 months
Study: 15631714
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Triptorelin (3.75 mg) at 6 weeks intervals in group A
Study: 15631714
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of Triptorelin (3.75 mg) at 4 weeks intervals in group B
Study: 17219967
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimes (SC and IM)
Study: 11705848
Drug: 4-hydroxyphenylretinamide (4-HPR)
Normalized name: 4-HPR
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hydroxyphenylretinamide (4-HPR) at 200 mg/day for 6 months (with a 3-day/month drug holiday)
Study: 22420538
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (SMT) including NIV if indicated
Study: 8365971
Drug: BCAA (leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (leucine + isoleucine + valine, 77 mg/kg)
Study: 8365971
Drug: Placebo (dextrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrose, 77 mg/kg)